Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Utsugi

Showing results (51-60 of 98) with videos related to

Pageof 10
Sort By:
Anticancer Research|June 6, 1998
Life prolonging effect of antitumor agents on postoperative adjuvant therapy in the lung spontaneous metastasis model in miceJ Shibata, K Murakami, M Abe, et al.
The Journal of International Medical Research|September 11, 2003
Angiotensin-converting enzyme gene polymorphism as a potent risk factor for developing microalbuminuria in Japanese patients with type 2 diabetes mellitus: a 9-year follow-up studyS Okuno, T Utsugi, T Ohno, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1995
Beta-cell-cytotoxic CD8+ T cells from nonobese diabetic mice use highly homologous T cell receptor alpha-chain CDR3 sequencesP Santamaria, T Utsugi, B J Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2000
Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipidsM Yoshida, T Kobunai, K Aoyagi, et al.
Journal of Human Genetics|June 11, 1998
Mutations in the hepatocyte nuclear factor-1 alpha gene (MODY3) are not a major cause of early-onset non-insulin-dependent (type 2) diabetes mellitus in JapaneseH Nishigori, S Yamada, T Kohama, et al.
Biochemistry|February 15, 2001
DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug actionJ A Byl, S D Cline, T Utsugi, et al.
Biochemistry|November 26, 1999
DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibitionJ M Fortune, L Velea, D E Graves, et al.
Mutation Research|September 1, 1988
Dose-response relationship for translocation induction in spermatogonia of the crab-eating monkey (Macaca fascicularis) by chronic gamma-ray-irradiationI Tobari, Y Matsuda, X H Gu, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2000
Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cellsH Minderman, C Wrzosek, S Cao, et al.
Cancer Research|March 1, 1992
Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferonC P Dinney, T Utsugi, I J Fidler, et al.
Pageof 10

Showing results (51-60 of 98) with videos related to

Sort By:
Pageof 10
Anticancer Research|June 6, 1998
Life prolonging effect of antitumor agents on postoperative adjuvant therapy in the lung spontaneous metastasis model in miceJ Shibata, K Murakami, M Abe, et al.
The Journal of International Medical Research|September 11, 2003
Angiotensin-converting enzyme gene polymorphism as a potent risk factor for developing microalbuminuria in Japanese patients with type 2 diabetes mellitus: a 9-year follow-up studyS Okuno, T Utsugi, T Ohno, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 1, 1995
Beta-cell-cytotoxic CD8+ T cells from nonobese diabetic mice use highly homologous T cell receptor alpha-chain CDR3 sequencesP Santamaria, T Utsugi, B J Park, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2000
Specific distribution of TOP-53 to the lung and lung-localized tumor is determined by its interaction with phospholipidsM Yoshida, T Kobunai, K Aoyagi, et al.
Journal of Human Genetics|June 11, 1998
Mutations in the hepatocyte nuclear factor-1 alpha gene (MODY3) are not a major cause of early-onset non-insulin-dependent (type 2) diabetes mellitus in JapaneseH Nishigori, S Yamada, T Kohama, et al.
Biochemistry|February 15, 2001
DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug actionJ A Byl, S D Cline, T Utsugi, et al.
Biochemistry|November 26, 1999
DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibitionJ M Fortune, L Velea, D E Graves, et al.
Mutation Research|September 1, 1988
Dose-response relationship for translocation induction in spermatogonia of the crab-eating monkey (Macaca fascicularis) by chronic gamma-ray-irradiationI Tobari, Y Matsuda, X H Gu, et al.
Cancer Chemotherapy and Pharmacology|January 27, 2000
Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cellsH Minderman, C Wrzosek, S Cao, et al.
Cancer Research|March 1, 1992
Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferonC P Dinney, T Utsugi, I J Fidler, et al.
Pageof 10